Home→Courses→Non-Clinical Safety Assessment of Novel Therapeutics Training Course
Biotechnology and Pharmaceutical Development
Non-Clinical Safety Assessment of Novel Therapeutics Training Course
Introduction
Non-Clinical Safety Assessment of Novel Therapeutics Training Course provides a comprehensive understanding of the critical processes involved in evaluating the safety of new drug candidates before clinical trials. In the ever-evolving landscape of pharmaceutical development, the preclinical phase is vital for identifying potential risks, ensuring patient safety, and complying with regulatory guidelines. This course emphasizes the integration of Good Laboratory Practices (GLP), toxicology testing, and pharmacology principles to evaluate the safety of novel therapeutics. Participants will learn to design, interpret, and apply non-clinical safety studies in the context of biopharmaceutical innovations and regulatory frameworks.
Equipped with in-depth case studies, industry insights, and expert-led methodologies, this training program is designed to help professionals in the pharmaceutical and biotech sectors stay ahead of trends and best practices. With a focus on innovative safety assessment approaches, participants will understand how to conduct toxicology assessments, analyze preclinical data, and navigate regulatory submissions for drug approval. The course blends theoretical concepts with practical, real-world applications, helping learners build the expertise needed to manage safety assessments effectively.
Programme Curriculum
Non-Clinical Safety Assessment of Novel Therapeutics Training Course
Introduction
Non-Clinical Safety Assessment of Novel Therapeutics Training Course provides a comprehensive understanding of the critical processes involved in evaluating the safety of new drug candidates before clinical trials. In the ever-evolving landscape of pharmaceutical development, the preclinical phase is vital for identifying potential risks, ensuring patient safety, and complying with regulatory guidelines. This course emphasizes the integration of Good Laboratory Practices (GLP), toxicology testing, and pharmacology principles to evaluate the safety of novel therapeutics. Participants will learn to design, interpret, and apply non-clinical safety studies in the context of biopharmaceutical innovations and regulatory frameworks.
Equipped with in-depth case studies, industry insights, and expert-led methodologies, this training program is designed to help professionals in the pharmaceutical and biotech sectors stay ahead of trends and best practices. With a focus on innovative safety assessment approaches, participants will understand how to conduct toxicology assessments, analyze preclinical data, and navigate regulatory submissions for drug approval. The course blends theoretical concepts with practical, real-world applications, helping learners build the expertise needed to manage safety assessments effectively.
Course Duration
10 days
Course Objectives
Understand the fundamentals of non-clinical safety assessment for novel therapeutics, focusing on toxicology, pharmacology, and GLP compliance.
Gain expertise in designing and interpreting preclinical safety studies for drug candidates in biotechnology and pharmaceutical industries.
Explore key toxicological principles, including acute toxicity, chronic toxicity, genotoxicity, and carcinogenicity testing.
Evaluate the role of non-clinical safety assessments in supporting regulatory approvals and ensuring patient safety.
Identify safety biomarkers and their application in the preclinical safety testing of novel therapeutics.
Master risk assessment strategies for evaluating the safety profile of new drug candidates.
Understand the regulatory guidelines set by agencies such as FDA, EMA, and ICH for non-clinical safety assessments.
Examine the role of animal models and in vitro assays in assessing therapeutic safety.
Learn the best practices for managing preclinical study data, including data analysis, reporting, and presentation.
Recognize the importance of safety pharmacology in understanding the cardiovascular, respiratory, and central nervous system effects of therapeutics.
Analyze case studies to understand real-world applications of non-clinical safety assessments in drug development.
Develop strategies for integrating non-clinical safety data into clinical trial designs to ensure a smooth transition from preclinical to clinical phases.
Implement advanced tools and technologies for safety assessment, including predictive toxicology and biomarker analysis.
Target Audience
Pharmaceutical industry professionals.
Biotech companies.
Toxicologists, safety officers, and regulatory affairs specialists.
Clinical research professionals.
Quality control and assurance managers in pharmaceutical and biotechnology sectors.
Research and development (R&D) teams.
Professionals working with biomarkers, pharmacology, and preclinical toxicology.
Regulatory affairs professionals.
Course Modules
Introduction to Non-Clinical Safety Assessment
Overview of non-clinical safety testing
Importance in drug development
Regulatory frameworks (FDA, EMA, ICH)
Key roles in non-clinical safety
Case studies: Future trends in safety assessment
Fundamentals of Toxicology
Types of toxicology studies
Acute vs. chronic toxicity
Genotoxicity and carcinogenicity
Toxicokinetics
Case studies of toxicology failures
Pharmacology and Safety Pharmacology
Principles of pharmacology in safety
Safety pharmacology testing (CNS, cardiovascular)
Regulatory requirements
Safety signals in pharmacology studies
Case studies: Real-life examples of pharmacology issues
Preclinical Study Design
Principles of study design
Selection of animal models
Statistical methods in toxicology studies
Dosage and administration in preclinical trials
Case study: designing a preclinical toxicology study
Biomarkers in Safety Assessment
What are biomarkers?
Types of safety biomarkers
Role in toxicology testing
Regulatory perspectives on biomarkers
Case studies of biomarker usage
Risk Assessment Methodologies
Introduction to risk assessment
Qualitative and quantitative methods
Safety margin calculations
Decision-making in safety assessment
Case study: risk assessment of a new therapeutic
Regulatory Requirements for Non-Clinical Safety
ICH guidelines for non-clinical studies
FDA and EMA safety requirements
GLP standards in safety testing
Reporting standards for non-clinical studies
Case study: preparing a safety assessment report
Predictive Toxicology
Introduction to predictive models
In silico tools for toxicity prediction
Advantages and limitations of predictive toxicology
Regulatory acceptance of predictive models
Case studies in predictive toxicology
In Vitro Safety Testing
Overview of in vitro models
Advantages of in vitro testing
Regulatory considerations
Types of in vitro assays used in safety testing
Case studies of in vitro testing in drug development
Advanced Preclinical Data Analysis
Data analysis techniques
Interpretation of toxicological data
Statistical significance in safety studies
Reporting and communicating results
Case study: data analysis in toxicology
Integrating Safety Data into Clinical Trials
From preclinical to clinical phase
How safety data impacts clinical design
Regulatory considerations for transition
Risk management strategies
Case study: integrating safety data
Safety in Biopharmaceutical Development
Unique challenges in biopharma safety
Biotechnology vs. traditional drug safety testing
Immunogenicity and its impact on safety
Risk assessment in biologics
Case study: safety issues in biopharma
Emerging Technologies in Safety Assessment
Nanotechnology and its safety concerns
Gene editing and safety assessments
Artificial intelligence in toxicology
Advances in predictive toxicology
Case studies: Future trends in non-clinical safety
Ethical and Legal Considerations in Non-Clinical Safety
Ethical issues in animal testing
Regulatory frameworks and animal welfare
Legal aspects of safety assessments
Alternative testing methods
Case study: ethical challenges in non-clinical safety testing
Case Studies in Non-Clinical Safety
Industry case studies on safety failures
Lessons learned from preclinical safety studies
Case studies: Best practices for conducting safety assessments
Innovative solutions for common issues
Key takeaways from real-world examples
Training Methodology
Interactive Online Learning.
Case Study Discussion.
Expert-Led Sessions.
Assessments and Quizzes
Collaborative Group Work.
Hands-On Workshops.
Register as a group from 3 participants for a Discount
Upon successful completion of this training, participants will be issued with a globally- recognized certificate.
Tailor-Made Course
We also offer tailor-made courses based on your needs.
Key Notes
a. The participant must be conversant with English.
b. Upon completion of training the participant will be issued with an Authorized Training Certificate
c. Course duration is flexible and the contents can be modified to fit any number of days.
d. The course fee includes facilitation training materials, 2 coffee breaks, buffet lunch and A Certificate upon successful completion of Training.
e. One-year post-training support Consultation and Coaching provided after the course.
f. Payment should be done at least a week before commence of the training, to FINESKILL TRAINING CENTER account, as indicated in the invoice so as to enable us prepare better for you.